( EXETER N.H.--(BUSINESS WIRE)--May 24 ...)Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions,Health

EXETER, N.H.--(BUSINESS WIRE)--May 24, 2007 - Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today announced that a late breaking abstract sponsored by the Company has been accepted for a poster presentation at the American Diabetes Association 67th Scientific Sessions in Chicago. The abstract, entitled "Results of a Randomized, Single-Dose, 2/3-Way Crossover Comparison Study of Intranasal Insulin Spray (Nasulin(TM)) and Injectable Fast-Acting Insulin (Humalog(R)) in Normal Nonsmoking and Smoking Subjects," will be included in the category of Clinical Therapeutics/New Technology - Insulin Delivery Systems and displayed Saturday, Sunday and Monday, June 23-25, 2007, in the General Poster Session in the Exhibit Hall.

As previously announced, Bentley had two other abstracts accepted, one for oral presentation and another for a poster presentation. The abstract on "Interim Results of a Randomized, Single-Dose, 4-Way Crossover, Pharmacokinetic Study of Intranasal Insulin Spray (Nasulin(TM)), Injectable Regular Insulin (Humulin R(R)), Injectable Fast-Acting Insulin (Humalog(R)), and Saline Nasal Spray in Patients with Type I Diabetes Mellitus," has been selected for oral presentation by Dr. Sherwyn L. Schwartz, M.D., of dgd Research, Inc., as part of the first session on Friday, June 22, 2007. In addition, the abstract, "Intranasal Insulin Spray (Nasulin(TM)) in Healthy Subjects: Choice of Nostril," will also be displayed Saturday through Monday, June 23-25, 2007, in the General Poster Session in the Exhibit Hall.

Founded in 1979 by Dr. Schwartz, the Diabetes & Glandular Disease Clinic is the largest private endocrine clinic in the United States with over 70,000 active patients, eight board certified endocrinologists, seven NPs/PAs and an ADA recognized diabetes education program. The research arm, dgd Research Associates, Inc., has a staff of over 250 employees and has cond
'"/>

Page: 1 2 3
Related medicine technology :

1. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
4. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
5. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
6. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
7. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
8. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
9. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
10. OXiGENE Abstracts Published in ASCO Program
11. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference